Replimune investors with losses encouraged to contact firm before Sept. 22nd deadline.

Replimune Group's stock price plummeted 45% after the company announced that a path forward for its lead cancer drug, RP1, under the accelerated approval pathway has not been determined. A securities class action lawsuit was filed, alleging that the company misled investors about the drug's success, leading to a 77% stock price crash. Investors with substantial losses are urged to contact Hagens Berman by September 22, 2025, to potentially join the case as lead plaintiff.

Replimune Group, Inc. (NASDAQ: REPL) experienced a significant downturn in its stock price on September 18, 2025, after the company announced that a path forward for its lead cancer drug, RP1, under the accelerated approval pathway has not been determined. This development follows the filing of a securities class action lawsuit, which alleges that the company misled investors about the drug's success, leading to a 77% stock price crash on July 22, 2025 Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman^[1].

The company completed a Type A meeting with the FDA on September 16 to discuss its Biologics License Application (BLA) for RP1 but could not identify a path forward under the accelerated approval pathway. This announcement caused the stock to fall by approximately 45% during intraday trading REPL 3-DAY DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman^[2].

The lawsuit, filed by Hagens Berman, claims that Replimune overstated the likelihood of success for its IGNYTE trial, which was deemed insufficiently well-designed by the FDA. The FDA's Complete Response Letter (CRL) cited issues such as patient heterogeneity and flawed trial design as reasons for the rejection. These previously undisclosed regulatory concerns led directly to the stock's dramatic collapse, resulting in significant losses for investors Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman^[1].

Investors with substantial losses are urged to contact Hagens Berman by September 22, 2025, to potentially join the case as lead plaintiff. The lead plaintiff deadline is September 22, 2025, and the class period spans from November 22, 2024, to July 21, 2025 REPL 3-DAY DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman^[2].

Hagens Berman, a national plaintiffs' rights law firm, is actively investigating whether Replimune misled its investors. The firm is seeking individuals who invested in Replimune and have substantial losses or knowledge that may assist the investigation. Whistleblowers who provide original information may be eligible for rewards under the SEC Whistleblower program REPL 3-DAY DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman^[2].